I like the chart.
Volume on the increase the last 3 days
All indicators are bullish.
support @ 0.80.....resistance @ 0.85
Is it time ???
http://stockcharts.com/def/servlet/SC.web?c=isv
ALAMEDA, Calif., Jun 09, 2005 (BUSINESS WIRE) -- InSite Vision Incorporated (ISV, Trade) - announced today that it has completed an in-vivo keratitis study in rabbits in collaboration with University Researchers. The results indicate that InSite Vision's AzaSite(TM) anti-infective (1% azithromycin) is effective in treating bacterial keratitis induced by Pseudomonas aeruginosa, a highly virulent gram-negative bacterium. Upon application of an AzaSite eyedrop to the infected eyes, the bacterial count was reduced by over three orders of magnitude. The results in the animal model were comparable to the results obtained with a fourth generation fluoroquinolone and other products currently on the market in a similar animal model.
Additionally, a recently completed time-kill study also suggests that the AzaSite formulation will sterilize the ocular surface, thus minimizing the chance of bacterial contamination during ocular procedures. The AzaSite formulation containing the DuraSite drug delivery system, eradicated a large variety of virulent gram-positive and gram-negative bacteria within one hour of application. The gram-negative bacteria tested included Pseudomonas aeruginosa and Serratia marsescens, two highly virulent ocular pathogens.
"The results of this study appear to confirm our long-held view that AzaSite is a broad spectrum antibiotic," stated S. Kumar Chandrasekaran, InSite Vision's president and chief executive officer. "We have previously shown that AzaSite is effective against eye infections induced by a common gram-positive bacterium, Staphylococcus aureus. Now we have also shown in-vivo that it is effective against a very virulent gram-negative bacterium, Pseudomonas aeruginosa. Taken together, these results show that AzaSite not only can potentially compete with fourth generation fluoroquinolones in terms of efficacy, but it may provide the added advantage of a significantly reduced dosing frequency."
"The extended and effective spectrum of antimicrobial activity exhibited by the AzaSite formulation further enhances the AzaSite product profile as a potential ocular infective market leader," stated David Heniges, Vice President of Marketing and Commercialization.
About InSite Vision
InSite Vision is an ophthalmic company focused on ocular infections, glaucoma and retinal diseases. The Company's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite(R), InSite Vision's patented drug-delivery vehicle, which offers the benefit of a less frequent, low-dosing regimen, attractive to both the eye-care patient and physician. The Company intends to seek to expand this "technology platform" to include additional indications and product options for the worldwide market.
In the glaucoma area, the Company has continued to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene(R) glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene. Additional information can be found at www.insitevision.com.
This press release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision. Such as the effectiveness of azithromycin as a broad-spectrum antibiotic; AzaSite's ability to compete against other products including fourth generation fluoroquinolones, potential dosing frequencies, and the market potential of azithromycin. Such statements entail a number of risks and uncertainties, including but not limited to: the confirmation in humans of the animal model study results discussed in this release; InSite Vision's ability to enroll patients in and to complete future clinical trials for AzaSite; the results of these clinical trials; InSite Vision's ability to commence, complete and file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for AzaSite, and receive approval from the FDA for the commercialization of AzaSite; InSite Vision's ability to obtain additional financing; InSite Vision's ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; InSite Vision's ability to negotiate, enter into and maintain collaborations and commercial agreements with potential corporate partners; its ability to obtain market acceptance of its products and product candidates; its reliance on third parties for the development, marketing and sale of its products; its ability to expand its technology platform to include additional indications and patent options; and the effects of its expense control activities on its operations and product development. For a discussion of these and other factors that could cause actual events or results to differ from those anticipated by our forward-looking statements, see the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q. These risk factors may not be exhaustive. Any projections and forward looking statements in this press release are based on the limited information currently available to InSite Vision, which is subject to change. New risk factors may emerge from time to time, and InSite Vision cannot predict such new risk factors, nor can it assess the impact, if any, of such new risk factors on our business or events described in any forward-looking statements. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.
Note to Editors: OcuGene is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite and OcuGene are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.
SOURCE: InSite Vision Incorporated
InSite Vision Incorporated
S. Kumar Chandrasekaran, 510-865-8800 (CEO)
Sandra Heine, 510-865-8800 (VP of Finance)
www.insitevision.com
Copyright Business Wire 2005
Chart looks healthy. But cant say if the news is already priced in it or not.
Hi Setravis,
This chart is showing power ;)
Nice advance on increasing volume on the last 2 sessions...
The only resistance I see is the $1 level...
good luck, but you don't need it ;)
regards,
Looks like it went and formed a,
Head and Shoulders Bottom (reversal) Pattern
Very nice volume today !!
Volume: 4,095,000.......... ;D
Avg Vol (3m): 320,658
Support @ 0.87...0.81...0.80
Resistance @ 0.90...1.00...1.25
Technicals
Record Volume
Most Actives
Percentage Gainer
Last Price Quote is:
17.65%above 13-day EMA
26.39%above 50-day EMA
RS Rating: 98
• INSITE VISION INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Wed 5:20pm)
• InSite Vision drug meets endpoint
bizjournals.com (Wed 5:07pm)
• InSite Says Drug Meets Primary Endpoint
AP (Wed 8:55am)
• InSite Vision Announces Positive Top-Line Results from First of Two Pivotal Phase 3 Clinical Trials
Business Wire (Wed 7:00am)
• InSite Vision to Hold Conference Call to Discuss Top Line Results of Pivotal Phase 3 Clinical Trial on November 30th
Business Wire (Tue 3:00pm)
Headline News Link: http://finance.yahoo.com/q/h?s=ISV
Press Release Source: InSite Vision Incorporated
InSite Vision Announces Positive Top-Line Results from First of Two Pivotal Phase 3 Clinical Trials
Wednesday November 30, 7:00 am ET
Pivotal Trial Succeeds in Reaching Primary Efficacy Endpoint of Clinical Resolution
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 30, 2005--InSite Vision Incorporated (AMEX:ISV - News) today announced positive top-line results from a pivotal phase 3 clinical trial of AzaSite(TM), a sterile, topical ophthalmic anti-infective solution containing 1.0% azithromycin formulated in DuraSite® (the Company's patented drug delivery system). In an international, controlled clinical trial, subjects with bacterial conjunctivitis (pink-eye) were treated with either AzaSite dosed twice a day for the first 2 days, followed by once a day for the next 3 days or 0.3% tobramycin dosed four times a day for 5 days. AzaSite demonstrated a clinical resolution rate of 80% as compared to 78% for tobramycin. This result shows that the clinical resolution rate of AzaSite is equivalent to tobramycin, the primary efficacy endpoint of the study, according to statistical criteria which were previously agreed to by the FDA. The bacterial eradication rate was also equivalent for both groups.
S. Kumar Chandrasekaran, Ph.D., InSite Vision's CEO stated, "The results of this phase 3 clinical trial demonstrate that AzaSite is effective against bacterial conjunctivitis using a significantly reduced dosing frequency. The clinical resolution rate of less frequently dosed AzaSite is comparable to the best selling ophthalmic antibiotic products. The reduced dosing frequency can lead to improved compliance, greater patient convenience and better therapeutic outcomes. This result is a major milestone achievement in the preparation for the AzaSite NDA filing in 2006."
Phase 3 study design
The phase 3 clinical trial was a double-blind, randomized, active-controlled study that enrolled patients ranging in age from 1 to 93 years with bacterial conjunctivitis. Patients with presumed bacterial conjunctivitis were enrolled on day 1 and a conjunctival culture was taken to demonstrate bacterial infection. All culture results were analyzed by a large central laboratory. The active control in the study was tobramycin, USP 0.3% ophthalmic solution, a broad-spectrum topical antibiotic. The treatment regimen lasted 5 days. The aim of the study was to show equivalent efficacy between patients dosed for 5 days with AzaSite versus tobramycin, AzaSite being less frequently dosed. There were a total of 47 clinical enrolling sites involved in the study; 41 in the United States and 6 in Latin America. A total of 746 subjects were enrolled in the study of which 316 had positive bacterial cultures. Among the culture positive subjects, 59% were pediatric and 41% were adult.
Treating bacterial conjunctivitis with AzaSite
The top line statistical analysis was performed on unblinded study data. Preliminary safety data from the phase 3 study showed that AzaSite was well tolerated in adult and pediatric patients. There were no reports of systemic drug sensitivity due to study medication. No serious adverse events were reported by the clinical sites. Ocular adverse events were minimal in frequency and equivalent between the two groups. Further, there were no reports of blurred vision related to the study medications. Further statistical analysis of the data is continuing. The final results will be presented in an upcoming international ophthalmic conference.
Conference Call
S. Kumar Chandrasekaran, Ph.D., Chief Executive Officer will host a conference call beginning at 10:30 a.m. Eastern Time today to discuss these top-line clinical results and answer questions. Dr. Eugene E. Protzko, clinical instructor at the University of Maryland School of Medicine and a principal investigator in the clinical trial will present his perspective on the study and answer questions during the call.
Individuals interested in listening to the conference call may do so by dialing (800) 475-3716 for domestic callers or 719-457-2728 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 800-203-1112 for domestic callers or 719-457-0820 for international callers. Callers will have to enter the Replay Passcode: 2904045.
The live conference call will also be available via the Internet on the investor relations section of the Company's Web site at www.insitevision.com, and a recording of the call will be available for 90 days following the completion of the call.
About InSite Vision
InSite Vision is an ophthalmic company focused on ocular infections, glaucoma and retinal diseases. The Company's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the successful results of phase 3 clinical testing currently underway and filing and approval of a NDA with the FDA, the Company currently expects to commercially launch AzaSite in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.
In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.
Additional information can be found at the Company's website, www.insitevision.com.
This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of initiation and completion of current and future clinical trials, the success thereof the timing of the filing an NDA with the FDA, expected marketing plan for AzaSite, the potential benefits and commercialization of AzaSite, and the timing and success thereof, and the Company's plans to pursue expanding the AzaSite "technology platform". Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain immediate additional financing. InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's clinical trials, particularly for AzaSite; InSite Vision's ability to commence, complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; InSite Vision's ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; InSite Vision's ability to obtain additional financing when needed; the effects of its expense control activities on its operations and product development; its ability to obtain regulatory approval and market acceptance of its products and product candidates, including its OcuGene glaucoma genetic test, AzaSite, ISV-205 and ISV-014; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; and determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K, as amended, and its quarterly reports on Form 10-Q. Any projections in this press release and/or conference call are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release and/or conference call is still valid at any later date.
Note to Editors: OcuGene is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite and OcuGene are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.
Contact:
InSite Vision Incorporated
S. Kumar Chandrasekaran/Sandra Heine, 510-865-8800
www.insitevision.com
or
Friedland Corporate Investor Services LLC.
Jeffrey Friedland /Jesse Blum, 866-356-0651
(Contacts for Investors and the Financial Community)
www.friedlandcorporateinvestorservices.com
--------------------------------------------------------------------------------
Source: InSite Vision Incorporated
Looks to be pulling back to support.
Support @ 0.87...0.81...0.80
Resistance @ 0.90...1.00...1.25
Recent CandleStick Analysis
Very Bearish
Dec-02-2005 Bearish Harami.........need futher confirmation.
Nov-28-2005 Bullish Engulfing
Technicals
Percentage Loser
MACD is Bullish
Stochastic is Bullish
Last Price Quote is:
10.47%above 13-day EMA
23.65%above 50-day EMA
RS Rating: 98
Fundamentals
Key Data:
Market Cap (M): $30.56
Moving up this morning
+11.11%.....Volume @......1,142,700..... ;D
Breakout.......
Volume: 1,317,200
Avg Vol (3m): 443,158
Technicals
Record Price High
Most Actives
Percentage Gainer
Last Price Quote is:
25.19%above 13-day EMA
39.10%above 50-day EMA
RS Rating: 98
Now @ +14.91%.....Volume @.....1,289,900
setravis,
Looks good. Applause. The print of 1.26 takes out the middle of the W-Bottom, 1.25, from March, 2004. Nice volume, too.
Thanks Melf Elf....
Applaud back at you for posting your chart work. Thanks ;)
Looking good for Loffigus in the Stock Picking Contest, His Pick !
I think he is holding 2nd Place at the moment, Gain of 20.00%
Volume: 1,075,400
Avg Volume (3m): 621,086
1st Place Loffigus....... ;D
Let's Rock.... 8)
Moving on...... :D
North bound this morning... ;D
+7.19%....Volume @.....211,700
Looking sweet indeed my fellow traders .... ;D
Volume: 1,569,600
Avg Vol (3m): 684,313
Technicals
Most Actives
Percentage Gainer
Last Price Quote is:
12.29%above 13-day EMA
28.92%above 50-day EMA
RS Rating: 98
YES that is awesome!!!!!!!! Great find much APPLAUSE!
Keepin my eye on this one, Likley buying on the break of the triangle.
Price action testing support currently, Hoping to see a bounce of this ascending trendline.
-fous
Quote from: fous on March 07, 2006, 10:48:58 PM
Keepin my eye on this one, Likley buying on the break of the triangle.
Price action testing support currently, Hoping to see a bounce of this ascending trendline.
-fous
I think she is headed that way Fous... ;D
Stochastic is in a good buy area, way down in the oversold area, has turned north.
Stochastic presents a buy opportunity. JMHO of course.
Recent CandleStick Analysis
Very Bullish
Mar-09-2006 Bullish Engulfing
Today's Candlestick Patterns:
White Opening Marubozu
Today a White Opening Marubozu was formed. This shows that the day opened and then the prices continued to go up all day long without coming below the opening level thus forming a long white body, however prices did not close at the high of the day and thus they created an upper shadow.
Support @ $1.54...1.36...1.30
Resistance @ $1.66...1.70...1.87
Technicals
Close Above the 13-day EMA
Percentage Gainer
Last Price Quote is:
3.00%above 13-day EMA
15.80%above 50-day EMA
RS Rating: 97
Candle patterns looking nice as well as bouncing off support. I see a nice risk/reward here. Buying at the open. For now i'll continue to hold as long as price action closes above the ascending triangle.
-fous
Press Release Source: InSite Vision Incorporated
InSite Vision to Hold Conference Call to Discuss Top Line Results of Second Phase 3 Clinical Trial on Tuesday, March 14th
Monday March 13, 7:00 am ET
ALAMEDA, Calif.--(BUSINESS WIRE)--March 13, 2006--InSite Vision Incorporated (AMEX:ISV - News) an ophthalmic therapeutics, diagnostics and drug-delivery company announced today that the Company will hold a conference call to discuss the top line results from the second of two required phase 3 clinical trials of AzaSite (azithromycin 1% solution in DuraSite®) on Tuesday, March 14, 2006.
S. Kumar Chandrasekaran, Ph.D., Chief Executive Officer, will host a conference call beginning at 4:30 p.m. Eastern Time on Tuesday, March 14, 2006 to discuss the top line results of the clinical trial and to answer questions.
Individuals interested in listening to the conference call may do so by dialing toll free (877) 407-0778 or (201) 689-8565. A telephone replay will be available for 48 hours following the conclusion of the call by dialing toll-free (877) 660-6853 or (201) 612-7415. All callers will have to enter the Play back account number 286 and Conference ID number: 195622.
The live conference call is being webcast by Vcall and can also be accessed via the investor relations section of the Company's website at www.insite.com or through www.InvestorCalendar.com. A recording of the call will be available for 90 days following the completion of the call.
About InSite Vision
InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. InSite Vision's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the successful results of phase 3 clinical testing currently underway and filing and approval of an NDA with the FDA, the Company currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.
In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.
Additional information can be found at the Company's website, www.insitevision.com.
This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of initiation and completion of current and future clinical trials, the success thereof, the timing of filing an NDA with the FDA, expected marketing plan for AzaSite, the potential benefits and commercialization of AzaSite, and the timing and success thereof, the expected date and forum for presenting AzaSite research results and the Company's plans to pursue expanding the AzaSite "technology platform." Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain additional financing, InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's AzaSite clinical trials; InSite Vision's ability to commence, complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; InSite Vision's ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others, determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205 and InSite's ability to present such results at an upcoming international conference. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K, as amended, and its quarterly reports on Form 10-Q. All forward looking statements in this press release and/or conference call are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release and/or conference call is still valid at any later date.
Note to Editors: OcuGene® is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite® and OcuGene® are trademarks of InSite Vision Incorporated.
Contact:
InSite Vision Incorporated
S. Kumar Chandrasekaran or Sandra Heine, 510-865-8800
www.insitevision.com
--------------------------------------------------------------------------------
Source: InSite Vision Incorporated
Nice movement again for this one today. "Let's Rock Fous!"
Volume: 1,097,200
Avg Vol (3m): 663,295
Technicals
Record Price High
Close Above the 13-day EMA
Most Actives
Record Price Break Out
Percentage Gainer
Last Price Quote is:
12.19%above 13-day EMA
26.13%above 50-day EMA
RS Rating: 98
InSite reports positive late-stage results for eye drops...
InSite Vision Announces Second of Two Phase 3 Clinical...
This is a strong trend.
Technicals
Most Actives
Percentage Gainer
Last Price Quote is:
18.82%above 13-day EMA
36.20%above 50-day EMA
RS Rating: 98
Press Release Source: InSite Vision Incorporated
InSite Vision Announces Second of Two Phase 3 Clinical Trials Results Meet Primary and Secondary Efficacy End Points
Tuesday March 14, 7:00 am ET
Preparations for AzaSite(TM) New Drug Application
ALAMEDA, Calif.--(BUSINESS WIRE)--March 14, 2006--InSite Vision Incorporated (AMEX:ISV - News) today announced top-line results from the second of two required phase 3 clinical trials to evaluate the safety and efficacy of AzaSite(TM) (1.0% azithromycin solution in DuraSite®) anti-infective eye drops in patients with bacterial conjunctivitis. In a study to show superiority of AzaSite relative to vehicle, patients treated with AzaSite had a significantly higher clinical resolution rate, the trial's primary efficacy end point and a significantly higher bacterial eradication rate, a secondary end point, than those receiving placebo. Importantly, the study also showed that AzaSite was safe and well tolerated. The data from which these top-line clinical results were drawn, will be reported at an upcoming ophthalmology conference.
S. Kumar Chandrasekaran, Ph.D., InSite Vision's CEO stated, "The completion of these two phase 3 clinical trials is a significant milestone for our company. The data demonstrates the success of our strategy to use the DuraSite platform to develop anti-infective therapies with reduced dosing frequency. The clinical resolution rate of less frequently dosed AzaSite is comparable to the best selling ophthalmic antibiotic products. The reduced dosing frequency can lead to improved compliance, greater patient convenience and better therapeutic outcomes. We look forward to presenting our data for scientific review and to the submission of our AzaSite NDA to the Food and Drug Administration this year."
Trial Design and Results
This second of two phase 3 trials was an international, double-blind, randomized, vehicle-controlled study that was conducted at 42 centers in the United States and 11 in Mexico and Central America. The trial enrolled 685 subjects of which 240 ranged in age from 1 to 16 years. Those subjects with confirmed bacterial conjunctivitis (pink-eye), a common infectious ocular disease, were evaluated for efficacy, whereas all subjects enrolled in the trial were evaluated for safety. Trial participants received eye drops of either placebo or AzaSite for 5 days. The drops were dosed twice a day for the first 2 days, followed by once a day for the next 3 days. Demographic characteristics were evenly distributed across treatment groups.
The Phase 3 trial was designed to compare the resolution of clinical signs and symptoms of bacterial conjunctivitis in subjects that had been treated with AzaSite versus those that had been treated with placebo. Top-line results showed that the clinical resolution rate, the trial's primary efficacy end point, was significantly higher in subjects treated with AzaSite than those treated with placebo (p less than 0.03). Furthermore, the bacterial eradication rate, the trial's secondary efficacy end point, was also significantly higher in the AzaSite treated group (p less than 0.001).
Preliminary safety data from the second phase 3 study showed that AzaSite was well tolerated in adult and pediatric subjects. There were no reports of systemic drug sensitivity due to study medication. No serious adverse events that were related to the study medications were reported by the clinical sites. Ocular adverse events were minimal in frequency and equivalent between the two groups. The statistical analysis of the entire dataset is still ongoing. The final results will be presented at an upcoming international ophthalmology conference.
About Bacterial Conjunctivitis
Bacterial conjunctivitis is a common ocular surface disease characterized by inflammation of the delicate skin and mucosa on the inside of the eyelids. The bacterial infections are contagious and generally accompanied by irritation, itching, foreign body sensation, watering, mucus discharge and redness (pink-eye). The bacterial form of the disease is more common in children than adults. In children, the most common bacterial species associated with acute conjunctivitis are Hemophilus influenzae, Streptococcus pnuemoniae, and Staphylococcus species. Among adults, bacterial conjunctivitis can be an important concern in contact lens wearers. The disease is self-limiting in most cases and usually resolves in 8-10 days. Topical antibiotics are often prescribed to control the public health risk of contagion and to shorten the duration of the disease.
Conference Call
S. Kumar Chandrasekaran, Ph.D., Chief Executive Officer will host a conference call beginning at 4:30 a.m. Eastern Time to discuss these top-line clinical results and answer questions along with Dr. Warren H. Heller, a principal investigator in the clinical trial and ophthalmologist in private practice in Phoenix, Arizona.
Individuals interested in listening to the conference call may do so by dialing toll free (877) 407-0778 or (201) 689-8565. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 or (201) 612-7415. Callers will have to enter the Play Back account number 286 and Conference ID number: 195622.
The live conference call is being webcast by Vcall and can also be accessed via the investor relations section of the Company's website at www.insite.com or through www.InvestorCalendar.com. A recording of the call will be available for 90 days following the completion of the call.
About InSite Vision Incorporated
InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. InSite Vision's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the successful results of phase 3 clinical testing currently underway and filing and approval of an NDA with the FDA, the Company currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.
In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.
Additional information can be found at the Company's website, www.insitevision.com.
This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of initiation and completion of current and future clinical trials, the success thereof, the timing of filing an NDA with the FDA, expected marketing plan for AzaSite, the potential benefits and commercialization of AzaSite, and the timing and success thereof, the expected date and forum for presenting AzaSite research results and the Company's plans to pursue expanding the AzaSite "technology platform." Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain additional financing, InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's AzaSite clinical trials; InSite Vision's ability to commence, complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; InSite Vision's ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others, determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205 and InSite's ability to present such results at an upcoming international conference. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K, as amended, and its quarterly reports on Form 10-Q. All forward looking statements in this press release and/or conference call are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release and/or conference call is still valid at any later date.
Note to Editors: OcuGene® is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite® and OcuGene® are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.
Contact:
InSite Vision Incorporated
S. Kumar Chandrasekaran or Sandra Heine, 510-865-8800
www.insitevision.com
--------------------------------------------------------------------------------
Source: InSite Vision Incorporated
InSite reports positive late-stage results for eye drops
Tue Mar 14, 2006 7:27 AM ET
March 14 (Reuters) - InSite Vision Inc. (ISV.A: Quote, Profile, Research) on Tuesday reported positive results from the second of two late-stage clinical trials to test its anti-infective eye drop AzaSite in patients with bacterial conjunctivitis.
The opthalmic company said in a statement it plans to submit a new drug application form to the U.S. Food and Drug Administration for AzaSite this year. (Reporting by Nupur Sen in Bangalore)
Rocking and a rolling.... 8)
Technicals
Record Price High........ ;D
Most Actives
Percentage Gainer
Last Price Quote is:
23.05%above 13-day EMA
42.82%above 50-day EMA
RS Rating: 99
im lovin this peg leg >:D
-fous
8)
Technicals
Last Price Quote is:
15.48%above 13-day EMA
37.61%above 50-day EMA
RS Rating: 98
Fundamentals
Key Data:
Market Cap (M): $30.56
Has been a Strong Move,Lets see if the momentum carries us.
I was ready for a dip but I am definitely holding on for a bigger ride.
Volume: 1,108,500
Avg Vol (3m): 793,877
Technicals
Record Price High
Percentage Gainer
Last Price Quote is:
17.50%above 13-day EMA
41.04%above 50-day EMA
RS Rating: 99
With this chart it is a stock worth holding onto with only a trailing stop.
This stock is poised for much higher prices over the coming months after a
consolidation period here.Stochastic bouncing up out of oversold area,buy zone.
Going in and out of stocks is not a strategy that will generate the great profits you really want. Finding a winner and sticking with it until it hits a trailing stop is the way to Real earnings.
Recent Company Developments
On November 30, 2005 InSite Vision reported top line results from the first of two phase 3 clinical trials of AzaSite eye drops. AzaSite is a sterile, topical ophthalmic anti-infective solution containing 1.0% azithromycin formulated in DuraSite(R) (InSite Vision's patented drug delivery system). The multicenter study was randomized, double masked, and active-controlled. In this trial, designed to show comparability with the marketed eye drop, tobramycin, with respect to the resolution of bacterial conjunctivitis, AzaSite demonstrated a clinical resolution rate of 80% as compared to 78% for tobramycin.
In December 2005 and January 2006, InSite Vision announced that debt financing had been secured, which would allow data generation and preparation of its NDA planned to be submitted to the FDA. In closings held in December 2005 and January 2006, InSite Vision raised an aggregate of $6.3 million before expenses through the issuance of Senior Secured Notes and the issuance of warrants to purchase 1,260,000 shares of Common Stock at an exercise price of $0.82 per share. InSite Vision also issued a warrant to purchase 200,000 shares of Common Stock to the placement agent in the transaction.
On January 13, 2006, InSite Vision announced the completion of enrollment of the second phase 3 clinical trial for AzaSite. The trial was a randomized, double masked, multicenter study that included patients from 1 - 96 years of age. The goal of the second study was to demonstrate superiority of AzaSite as compared to a vehicle (a placebo that does not contain any active drug substance) in the clinical resolution of the bacterial conjunctivitis. Clinical resolution was the primary efficacy endpoint. A secondary endpoint was bacterial eradication. On March 14, 2006, top line results were reported from this second clinical trial. Patients treated with AzaSite had a significantly higher clinical resolution rate, the trial's primary efficacy end point and a significantly higher bacterial eradication rate, a secondary end point, than those receiving the vehicle.
On February 22, 2006 InSite Vision reported that two abstracts were accepted for presentation at the upcoming meeting of the Association for Research in Vision and Ophthalmology at the Fort Lauderdale Convention Center in Ft. Lauderdale, Florida, to be held April 30 - May 4, 2006. The presentations will describe the results of the AzaSite vs. tobramycin clinical trial.
INSITE VISION INC Files SEC form 10-K, Annual Report
http://biz.yahoo.com/e/060331/isv10-k.html
Repeat myself...... ;D
With this chart it is a stock worth holding onto with only a trailing stop.
This stock is poised for much higher prices over the coming months after a
consolidation period here.Stochastic bouncing up out of oversold area,buy zone.
Going in and out of stocks is not a strategy that will generate the great profits you really want. Finding a winner and sticking with it until it hits a trailing stop is the way to Real earnings.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Technicals
Record Price High
Close Above the 13-day EMA
Most Actives
Percentage Gainer
Last Price Quote is:
10.98%above 13-day EMA
32.40%above 50-day EMA
RS Rating: 99
Press Release Source: Rodman & Renshaw, LLC
Rodman & Renshaw, LLC Announces Investment Opinion on InSite Vision, Inc. with a Market Outperform Rating
Friday March 31, 2:56 pm ET
Analyst Sets 12 Month Target Price of $4
NEW YORK--(BUSINESS WIRE)--March 31, 2006--Rodman & Renshaw, LLC initiated research coverage of InSite Vision, Inc. (AMEX: ISV - News) with a Market Outperform Rating and a 12-month price target $4. Ilya Kravets, Senior Specialty Pharmaceuticals Analyst, issued the report.
About Rodman & Renshaw, LLC
Rodman & Renshaw is a privately held, full-service investment bank committed to fostering the long-term success of growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. More information is available at www.rodmanandrenshaw.com
None of the research analysts or the research analyst's household has a financial interest in the securities of InSite Vision, Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of February 28, 2006, neither Rodman & Renshaw, LLC nor its affiliates beneficially own 1% or more of any class of common equity securities of InSite Vision, Inc.
Neither the research analyst nor Rodman & Renshaw, LLC has any material conflict of interest with InSite Vision, Inc., of which the research analyst knows or has reason to know at the time of publication of this research report.
Rodman & Renshaw, LLC or its affiliates did not receive compensation from InSite Vision, Inc. for investment banking services within the last twelve months and Rodman & Renshaw, LLC intends to seek compensation from InSite Vision, Inc. for investment banking services within three months, following publication of the research report.
Neither the research analyst nor any member of the research analyst's household nor Rodman & Renshaw, LLC serves as an officer, director or advisory board member of InSite Vision, Inc.
Rodman & Renshaw, LLC does not make a market in InSite Vision, Inc.' securities as of the date of this research report.
The above information is not intended to be used as a primary basis of investment decisions. It is not a representation by Rodman & Renshaw, LLC or an offer or the solicitation of an offer to buy any security. Before investing in InSite Vision, Inc., you should carefully consider your risk tolerance and financial objectives.
Contact:
Rodman & Renshaw, LLC
William A. Iommi, 212-356-0549
Fax: 212-581-5690
--------------------------------------------------------------------------------
Source: Rodman & Renshaw, LLC
Outstanding......
Volume: 1,714,000
Avg Vol (3m): 843,818
Technicals
Record Price High
Close Above the 13-day EMA
Most Actives
Percentage Gainer
Last Price Quote is:
15.59%above 13-day EMA
37.89%above 50-day EMA
RS Rating: 99
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: N/A
keeps a moving.....
Technicals
Record Price High
Percentage Gainer
Last Price Quote is:
17.57%above 13-day EMA
41.28%above 50-day EMA
RS Rating: 99
Fundamentals
Coverage Initiated: Mkt Outperform
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform
• Coverage initiated on Insite Vision by Rodman & Renshaw
Briefing.com (Tue 2:06pm)
Legs to stand on....
Great chart
Technicals
Percentage Gainer
Last Price Quote is:
10.26%above 13-day EMA
34.91%above 50-day EMA
RS Rating: 98
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform
A dip ...headed back up.
Technicals
Close Above the 13-day EMA
Percentage Gainer
Last Price Quote is:
3.85%above 13-day EMA
22.54%above 50-day EMA
RS Rating: 98
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform
Awesome chart....... :o
Technicals
Record Price High
Last Price Quote is:
8.37%above 13-day EMA
27.92%above 50-day EMA
RS Rating: 98
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform
I first bought isv on 3/13/06 just before the breakout. and held thru the conference call day... yes the day that the stock dipped within seconds of the opeing bell but ramped up almost immediately. I did a search a few days ago and did not find this post, hum ... interesting... Travis, what is your take on this stock...
Thanks
B
ISV made an interesting move today.. formed a hammer.... from its past performance, ISV usually tend to shakeout before it setitself to move up.....
not too late to get in ....
cheers
B
Look for new 52 week high in ISV next week.
Technicals
Close Above the 13-day EMA
Percentage Gainer
Last Price Quote is:
8.76%above 13-day EMA
18.31%above 50-day EMA
RS Rating: 97
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform
Still holding strong:P
isv has been behaving very welll.... despite all the down acion...
;)
For every financial reason you should invest in this company.
There is insider buying and the stock is increasing in value !
Pretty good relative strength.
Technicals
Last Price Quote is:
0.25%above 13-day EMA
8.87%above 50-day EMA
RS Rating: 97
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform
Quote from: setravis on May 21, 2006, 07:58:37 PM
For every financial reason you shouldn't invest in this company.
Do u mean should???????
Quote from: beroznikmal on May 21, 2006, 08:16:15 PM
Quote from: setravis on May 21, 2006, 07:58:37 PM
For every financial reason you shouldn't invest in this company.
Do u mean should???????
Yes , should. Thanks for the catch of my typing mistake... :-[
Excuse me for my error....Corrected it on my post. ::)
wow just trying to help out.. sorry for trying.... ::)
>:D
Thank you for the help,and excuse me for my typing error... ;D
Did you misunderstand me?
Applaud for the help.... ;)
;)
;D
Technicals
Record Price High
Percentage Gainer
Last Price Quote is:
10.09%above 13-day EMA
21.63%above 50-day EMA
RS Rating: 98
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Buy
Holding up nice in this market.
Recent CandleStick Analysis
Jun-14-2006 Bullish Engulfing
The last two candlesticks formed a Bullish Engulfing Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires confirmation
White Marubozu
was formed. This shows that the buyers controlled the price action from the first trade to the last trade.
Stochastic is Bullish
MACD is Bearish
Support @ $2.27...2.17...2.07
Resistance @ $2.39...2.48...2.69...2.88
Technicals
Close Above the 50-day EMA
Close Above the 13-day EMA
Percentage Gainer
Last Price Quote is:
0.22%above 13-day EMA
2.49%above 50-day EMA
RS Rating: 97
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Buy
More...
good analysis starvis...
I was happy to see the white candle today... however not too happy with the volume
Hopefully we'll see more interest tomorrow...
B
The move back to the upside continues.....
Indicators have turned north, MACD..Stochastic..RSI
Broke through minor resistance @ $2.39
Showing a possible buying opportunity as K line is about to cross on top of D line indicating buy signal, while ROC is still at oversold level. One indicator to watch is MACD, MACD is below 0, a weak signal.
Support @ $ 2.39...2.25...2.07
Resistance @ $2.48...2.69...2.89
Volume: 749,300
Avg Vol (3m): 619,118
Technicals
Close Above the 50-day EMA
Close Above the 13-day EMA
MACD is Bearish
Stochastic is Bullish
Last Price Quote is:
7.66%above 13-day EMA
10.10%above 50-day EMA
RS Rating: 97
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Buy
today .. was a good day.. healthy volume...
:P
ISV took a hammering these 3 days..
Technically, there was a bearish raising wedge formation which morphed into a head and shoulder formation.
Fundamentally, Investors are nervous since, Kumar had promised some kind of deal would be made by the end of June and there is only 8 more days left...
B
Press Release Source: InSite Vision Incorporated
InSite Vision to Present Results From Second of Two Pivotal Phase 3 Clinical Trials
Thursday August 3, 9:00 am ET
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 3, 2006--InSite Vision Incorporated (AMEX:ISV - News), an ophthalmic company focused on ocular infections, glaucoma and retinal diseases, announced today the acceptance of two abstracts related to its second pivotal trial of the topical eye drop antibiotic, AzaSite (1% azithromycin in DuraSite®). The vehicle-controlled, prospective, multi-center, bacterial conjunctivitis trial showed AzaSite was superior to the vehicle in both clinical resolution of the signs and symptoms of bacterial conjunctivitis as well as bacterial eradication. The efficacy and safety data will be presented at the upcoming meeting of the American Academy of Ophthalmology in Las Vegas, Nevada to be held November 11 - 14, 2006. The presentation schedule is as follows:
Efficacy of Azithromycin 1% Eye Drops vs. Vehicle as First-Line Therapy for Bacterial Conjunctivitis, Mark Abelson, MD, Warren Heller, MD, and the AzaSite Clinical Study Group.
Safety and Tolerability of 1% Azithromycin Eye Drops as Anti-infective Therapy for Bacterial Conjunctivitis, Warren Heller, MD, Mark Abelson, MD, and the AzaSite Clinical Study Group.
AzaSite contains 1% azithromycin, a broad-spectrum antibiotic. InSite Vision Inc. has completed two phase 3 studies. The results of these studies were submitted to the FDA on June 28, 2006 as part of the NDA to gain regulatory approval of AzaSite.
The first phase 3 study was a double-blinded, prospective, active-controlled bacterial conjunctivitis trial. It showed AzaSite dosed twice daily for the first 2 days and once daily for 3 more days was equivalent to tobramycin dosed four times daily for 5 days in resolving clinical signs and symptoms of bacterial conjunctivitis and eradicating offending bacteria. The second phase 3 study was a double-blinded, prospective, vehicle-controlled trial. It showed AzaSite was superior to the vehicle in both clinical resolution of the signs and symptoms of bacterial conjunctivitis and bacterial eradication. Both trials revealed a superior safety profile of AzaSite.
Kumar Chandrasekaran, Ph.D., InSite Vision's Chief Executive Officer, stated, "These clinical trial results support AzaSite's value proposition of established efficacy and coverage with the convenience and compliance of a once-a-day dosing regimen."
About InSite Vision Incorporated
InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. The Company's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the filing and approval of an NDA with the FDA, the Company currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.
In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.
Additional information can be found at the Company's website, www.insitevision.com.
This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the anticipated closing of the private placement and the proposed use of proceeds therefrom. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain additional financing in the near future, InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's clinical trials, particularly for AzaSite; the ability to complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; the ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; its ability to obtain regulatory approval and market acceptance of its products and product candidates, including its OcuGene glaucoma genetic test, AzaSite, ISV-205 and ISV-014; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors". Any projections in this press release are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.
Note to Editors: OcuGene® is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite® and OcuGene® are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.
Contact:
InSite Vision Incorporated
S. Kumar Chandrasekaran or Sandra Heine, 510-865-8800
www.insitevision.com
or
Ashton Partners
888-857-7839 (Investors)
www.ashtonpartners.com
--------------------------------------------------------------------------------
Source: InSite Vision Incorporated
Stochastic coming out of oversold.
Technicals
Percentage Gainer
Last Price Quote is:
8.92%above 13-day EMA
-11.40%below 50-day EMA
RS Rating: 6
Fundamentals
Earnings Expected on Aug 14
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Buy
Press Release Source: InSite Vision Incorporated
InSite Vision Announces 2nd Quarter, 2006 Earnings Conference Call to Be Held on August 14, 2006
Monday August 7, 7:00 am ET
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 7, 2006--InSite Vision Incorporated (AMEX:ISV - News), an ophthalmic therapeutics, diagnostics and drug delivery company, announced today that the company will release 2006 second quarter financial results on Monday, August 14, 2006.
Kumar Chandrasekaran, PhD, Chief Executive Officer, and Sandra Heine, Vice President, Finance and Administration, will host a financial community conference call beginning at 9:00 a.m. EST on Monday, August 14, 2006 to discuss these results.
Individuals interested in listening to the conference call may do so by dialing (877) 407-0778 for domestic callers and (201) 689-8565 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will have to enter the conference ID 210914.
The live conference call will also be webcast and available on the Internet at www.InvestorCalendar.com as well as the Company's website at www.insitevision.com. A recording of the call will be available for 90 days following the completion of the conference.
About InSite Vision Incorporated
InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. The Company's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the filing and approval of an NDA with the FDA, the Company currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.
In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.
Additional information can be found at the Company's website, www.insitevision.com.
This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of filing an NDA with the FDA, the Company's ability to obtain FDA approval of its NDA and the anticipated date of commercialization of AzaSite. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's clinical trials, particularly for AzaSite; the ability to complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; the ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; its ability to obtain regulatory approval and market acceptance of its products and product candidates, including its OcuGene glaucoma genetic test, AzaSite, ISV-205 and ISV-014; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors." Any forward looking statements or projections in the conference call are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.
Note to Editors: OcuGene® is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite® and OcuGene® are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.
Contact:
Ashton Partners
Barry Hutton ,888-857-7839 (Investors)
www.ashtonpartners.com
--------------------------------------------------------------------------------
Source: InSite Vision Incorporated
Broke above the 200-day MA.
Technicals
Close Above the 50-day EMA
Percentage Gainer
Last Price Quote is:
23.19%above 13-day EMA
5.00%above 50-day EMA
RS Rating: 20
Fundamentals
Earnings Expected on Aug 14
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Buy
interesting chart & news IMO >:D
Insite Drug Under Review by the FDA
Monday August 28, 12:28 pm ET
Insite Vision Awaiting FDA Decision on Conjunctivitis Treatment Candidate.
ALAMEDA, Calif. (AP) -- Insite Vision Inc., maker of treatments for eye diseases, said Monday it asked the Food and Drug Administration to approve its bacterial conjunctivitis treatment, Azasite.
The new drug application, now under review by the FDA, includes results from three clinical trials involving 698 patients. The studies showed Azasite, the company's lead product candidate, were effective in reducing symptoms and getting rid of bacteria. The company hopes to launch the product early next year.
Bacterial conjunctivitis is a common condition in which the mucous membrane of the eye becomes infected.
Shares of Insite rose 9 cents, or 5.6 percent, to $1.70 on the American Stock Exchange in midday trading. The stock has traded between 48 cents and $2.70 over the last 52 weeks.
This one of my picks for tomorrow O, you hoppin in?
ISV approved for NDA filing review:
QuoteALAMEDA, Calif.--(Business Wire)--Aug. 28, 2006-- InSite Vision Incorporated (AMEX:ISV) -- an ophthalmic therapeutics, diagnostics and drug delivery company, today announced the U.S. Food and Drug Administration has accepted for filing and comprehensive review, InSite Vision's NDA for AzaSite (azithromycin 1% ophthalmic solution), indicated for the treatment of bacterial conjunctivitis. AzaSite is formulated with "DuraSite," InSite Vision's patented drug delivery vehicle which enhances the retention time of the antibiotic on the surface of the target tissue.
The NDA contains data from two phase 3 clinical trials in which 698 patients were treated with AzaSite. Data from these studies demonstrated that when AzaSite was administered twice daily on the first two days, then once daily on days 3-5, it provided clinically and statistically significant improvements in clinical resolution of symptoms, and bacterial eradication compared to placebo, and was equivalent in clinical resolution and bacterial eradication when compared to tobramycin administered four times a day.
S. Kumar Chandrasekaran, Ph.D., InSite Vision's chief executive officer stated, "Today's announcement of the FDA acceptance and review of InSite Vision's NDA is a significant milestone which brings us one step closer to achieving our ultimate goal of the commercialization of our lead AzaSite product in early 2007. We expect a timely review by the FDA and look forward to hearing from them regarding next steps."
-fous
Oliver and fous,
Volume was lacking, but that was a Double Ascending Triangle breakout yesterday. There's a little Ascending Triangle (August 7 - to yesterday's breakout) nested within the larger pattern. Nice find. I get about the same target as fous. Applaud you guys.
;)
Technicals and Growth Potential !
Microcap, strong technicals, potential near term 13/50 day crossover,
recent FDA submission.
Looks to be a cup and handle formation in the making......
Recent CandleStick Analysis
Bullish
Aug-28-2006 Bullish Harami
Support @ $1.78...1.69...1.52...1.45
Resistance @ $1.87...2.01...2.08...2.15
MACD is Bullish
Stochastic is
52wk Range: 0.48 - 2.70
Technicals
Close Above the 50-day EMA
Last Price Quote is:
10.49%above 13-day EMA
10.12%above 50-day EMA
RS Rating: 5
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Buy
Does this break of support at 1.80 does some technical damage even if it closes at1.80 or above?
Quote from: Se7en on August 31, 2006, 01:09:05 PM
Does this break of support at 1.80 does some technical damage
Se7en,
We never want to see a stock go back below a breakout because, obviously, we have to consider the possibility that we had a false breakout. (We need a cursing face on the toolbar when that happens).
For example, if it's a false breakout, the Ascending Triangle might have "morphed" (changed) into a Bear Flag (the parallel lines drawn in red).
It isn't technically damaged at this point, but it would be if we take out the ascending line (blue) and the bottom of the "possible" Bear Flag (red)
Quote
even if it closes at1.80 or above?
As long as a stock closes at or above a breakout (1.80 in this case) I consider the target(s) still to be IN PLAY.
A close back below 1.80, the target goes ON HOLD until we see what's going on. That's a "gut check" time when a target goes ON HOLD. Do we still want to hold it? What do we like about the stock, etc. I sometimes "abandon ship" when a stock goes ON HOLD.
If the support that I mentioned (at about 1.65) gets broken, the upside target is CANCELLED, and we then would have a downside target IN PLAY, based on the measurement of the possible Bear Flag.
Quote from: Melf Elf on August 30, 2006, 05:40:00 AM
Oliver and fous,
Volume was lacking, but that was a Double Ascending Triangle breakout yesterday.
The lack of volume on the breakout is something that I would consider in the decision-making process.
I also would consider the fact that the 50DMA just had a Bearish Cross below the 200DMA a week ago, etc.
Good luck if you have it.
Thx Melf Elf, very informative! :)
ALAMEDA, Calif., Oct 02, 2006 (BUSINESS WIRE) -- InSite Vision Incorporated (ISV, Trade) -- an ophthalmic therapeutics, diagnostics and drug delivery company, is pleased to announce that Kumar Chandrasekaran, Ph.D., Chief Executive Officer will host the Company's 2006 Annual Shareholder meeting beginning at 1:00 pm EDT, Tuesday, October 3, 2006.
Immediately after the conclusion of the meeting, InSite Vision's management team will discuss key corporate initiatives including updates on the New Drug Application with the FDA for its lead topical anti-infective product AzaSite(TM) (ISV-401), new efforts surrounding its next major program, AzaSite Plus (ISV-502) and other corporate activities.
During the meeting the Company's stockholders will be asked to vote on three proxy items as outlined below:
-- The re-election of five directors to the Board of Directors of the Company;
-- An approval of an amendment to the Company's Restated Certificate of Incorporation (the "Certificate" or the "Restated Certificate of Incorporation") increasing the number of authorized shares of common stock from 120,000,000 to 240,000,000 shares; and
-- The ratification of the appointment of Burr, Pilger & Mayer LLP as independent public accountants of the Company for the fiscal year ending December 31, 2006.
The corporate presentation will be available live via webcast. To access the webcast, please go to the investor relations section of the Company's website at www.insitevision.com. A taped recording of the presentation will also be available after Tuesday October 3, 2006 for approximately one month.
About InSite Vision Incorporated
InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. InSite Vision's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the approval of its NDA with the FDA, InSite Vision currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.
In the glaucoma area, InSite Vision continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the InSite Vision's commercially available OcuGene(R) glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.
Additional information can be found at our website, www.insitevision.com.
This news release and the webcast provided for hereunder contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the Company's ability to obtain FDA approval of its NDA, discussion of he Companyh's efforts to engage a corporate partner for its AzaSite product, the anticipated date of commercialization of AzaSite and other product candidates, and the Company's product development plans. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain substantial additional funding to continue its operations; the results of InSite Vision's clinical trials; the ability to obtain FDA approval of its AzaSite NDA from the FDA for the commercialization of AzaSite and its other product candidates; the ability of InSite Vision to enter into a corporate collaboration for its AzaSite and other product candidates; the ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; its ability to obtain regulatory approval and market acceptance of its products and product candidates, including its OcuGene glaucoma genetic test, AzaSite, ISV-205 and ISV-014; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205 . Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors." Any forward looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.
Note to Editors: OcuGene(R) is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite(R) and OcuGene(R) are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.
SOURCE: InSite Vision Incorporated
Ashton Partners
Barry Hutton, 888-857-7839
www.ashtonpartners.com
Copyright Business Wire 2006 ********************************************************************** As of Thursday, 09-28-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 08-07-2006 for ISV @ $1.73. For more information on Comtex SmarTrend? Alert, contact your market data provider or go to CSTADirect.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2006 Comtex News Network, Inc. All rights reserved.
Maintaining support.....
52wk Range: 0.59 - 2.70
Volume: 135,500
Avg Vol (3m): 236,533
Technicals
Last Price Quote is:
4.68%above 13-day EMA
1.06%above 50-day EMA
RS Rating: 71
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Buy
setravis, you are invested or are you waiting for the BO?
Quote from: la-onda on October 03, 2006, 12:10:22 PM
setravis, you are invested or are you waiting for the BO?
Invested........ 8)
Have been holding this one many moons past ;D
Quote from: Melf Elf on August 31, 2006, 02:57:00 PM
For example, if it's a false breakout, the Ascending Triangle might have "morphed" (changed) into a Bear Flag (the parallel lines drawn in red).
The Bullish Double Ascending Triangle breakout did, in fact, "morph" (change) into a Bear Flag. :P
Quote
It isn't technically damaged at this point, but it would be if we take out the ascending line (blue)
The Ascending trendline broke to the downside on September 6. :P
Quote
and the bottom of the "possible" Bear Flag (red)
The bottom of the Bear Flag broke on a gap down opening the next day, Septermber 7. :P
Quote
If the support that I mentioned (at about 1.65) gets broken, the upside target is CANCELLED,
The upside targets were CANCELLED on the break of the Bear Flag.
Quote
and we then would have a downside target IN PLAY, based on the measurement of the possible Bear Flag.
The break of the Bear Flag put targets of 1.46 (the bottom of the Bear Flag) IN PLAY, and 1.21 IN PLAY. The 1.46 target MADE. The 1.21 target hasn't. The September 27 low is 1.41
Math for the 1.21 target:
High of the Bear Flag: 1.97
Low of the Bear Flag: 1.46
1.97 - 1.46 = 0.51 points
The Bear Flag broke at 1.72 - 0.51 points = 1.21 IN PLAY
Targets don't always get MADE, like the Ascending Triangle targets that got CANCELLED when the Bear Flag formed, then broke to the downside, so we might not see the 1.21 target. Just be aware, especially with 50/200 DMAs inverted, that it's still IN PLAY.
Quote from: Melf Elf on August 31, 2006, 02:57:00 PM
If the support that I mentioned (at about 1.65) gets broken, the upside target is CANCELLED, and we then would have a downside target IN PLAY, based on the measurement of the possible Bear Flag.
At today's low of 1.24, ISV is within pennies of a downside target IN PLAY.
From the false breakout (Bull Trap) at 1.81, ISV is
down 31.49%From the Bear Flag break at 1.68, ISV is
down 26.2%.UGH.
"Don't let a small loss (The break of the Bear Flag) turn into a disaster."
I opened a position at 1.25 this morning, good bounce so far....
This one really caught me by surprise today. I wasn't expecting such a quick move in one session....but they are welcome anytime.... >:D
I sold 1/2 of my position at 1.49 just before the close, after all that was a quick 20% profit.
Volume was kind of good but it ran so fast with no news (that I know of), plus it couldn't really break the 1.50 resistance and we also have 50 and 200 ema just above;so it was kind of risky not to take any profits off the table...
GLTA
Couldn't resist yesterday buying back the 1/2 I had sold.
I will wait for ISV to break above 1.50 for greener pastures or kiss it good bye if it closes below 1.35.
Watch volume and price action closely on this one from now into next week as it wants to breakout above the 200ema and 1.50 for good........
Trade is going as expected......200 ema will be taken out any day this week, maybe even tomorrow..moving my stop up to a close below 1.40
ISV going higher now......
Moving my stop to <1.50 on close to protect my profits.
Quote from: bocasva on November 26, 2006, 06:23:31 PM
Moving my stop to <1.50 on close to protect my profits.
Bocasva,
You've done a very nice job on this trade. Applause.
Coming off the 1.24 low, ISV initially got stopped at the red trendline resistance (Purple #2), but managed to get through it last Tuesday (Purple #4). Unfortunately, that didn't hold up, and the pattern in purple is looking like a Bear Flag.
Wednesday's low was 1.48, just a hair below the 50DMA which is at 1.4976, then it recovered, to close at 1.56. Friday, it hung around there on "no volume" post-holiday trading. That's fine.
It looks like it wants to go higher, and take out near-term 1.65-1.67 resistance, doesn't it? I'll post you the Ichimoku Kinko Hyo chart next, which indicates that ISV is well-positioned to move higher.
But, I think you're wise to protect your profits, in case it doesn't.
Good luck with your trade. You've managed it very well. ;)
Ichimoku Kinko Hyo chart:
Thanks Melf Elf for the detailed TA.
ISV having a hard time staying away from 1.50 so I might have to jump ship tomorrow.
Quote from: bocasva on November 27, 2006, 10:37:28 PM
ISV having a hard time staying away from 1.50 so I might have to jump ship tomorrow.
bocasva,
Probably not a bad idea. ;)
The 50DMA now is
1.496, just below yesterday's low of
1.50, so it held on right there. Last Wednesday's low was 1.48, so if 1.47 gets printed today, good chance that ISV will head at least for the bottom of the Kumo (Cloud)/ the bottom of the Flag.
Data points for today, November 28:
1.425 is the bottom of the Kumo (Cloud)
1.404 is the bottom of the Flag (pattern in purple)
Good luck! I hope it rallies for you.
Finally a nice bounce off 1.50 support.
Quote from: bocasva on November 30, 2006, 09:44:29 PM
Finally a nice bounce off 1.50 support.
Bocasva,
This is shaping up very, very nicely! If ISV weren't so thinly traded, I would buy it right here.
Quote from: bocasva on November 26, 2006, 06:23:31 PM
Moving my stop to <1.50 on close to protect my profits.
I'm all for protecting profits, but you might want to rethink that stop. You don't want to put it so tight that you get jiggled out of what looks to be a very nice play. It's YOUR MONEY, so naturally, you decide what kind of risk you want to take, but see what you think of this:
1. ISV had a "false breakout" of an Ascending Triangle (pattern in blue) that morphed into a Bear Flag (see the chart that I posted to you before).
2. Then it came down for a "possible" Double Bottom, at 1.20 - 1.24.
3. After the first rally attempt off 1.24, ISV came back and found support at the 8-day (solid green) and 22-day (solid red), which had a Bullish Cross. Nice.
4. MACD came back to its signal line on November 13, then banged higher the next day. Nice.
5. The 13/21 RSIs, and the next pairing in the Fibonacci Sequence, the 21/34RSIs, both gave a Buy Signal on November 16, on the print of 1.49 (just below your stop, but that might get tested one more time, and you'll be stopped out).
6. On the current selloff, the RSIs have come into Bullish Synchronicity again, only this time, the next pairing in the Fibonacci Sequence, the 34/55RSIs also have come into Bullish Synchronicity. A print of 1.59 here is a Buy Signal. ISV closed at 1.57.
7. MACD went up through the zero line on November 20, came back toward its signal line during the current selloff, then ticked higher yesterday. Nice.
8. The rally off the 1.24 Double Bottom to 1.65 established the second data point for the 1.67 - 1.65 neckline of a Bullish Inverse H&S. The current selloff is the Right Shoulder.
Although this has been somewhat of a nail-biter for you, wanting to see 1.50 hold to protect your nice gain, and also wanting to see that danged thing BREAK OUT, this selloff has been very purposeful and won't have been for naught if that 1.67-1.65 neckline gets taken out to the upside.
Purposeful, in that the technicals are "in gear" for a rally, the Right Shoulder of the Bullish Inverse H&S is near completion, and ISV is "good to go" on the upside, on a breakout above 1.67-1.65.
If it does break out, 2.08 will be IN PLAY. Math is on the chart.
If 2.08 gets MADE, that also will be a breakout of a W-Bottom, above the August 30 high of 1.97, which would be a larger pattern breakout, and which would put a higher target IN PLAY. We can discuss that "if/when..."
Back to your stop: YOUR MONEY, but given the Bullish factors here, you might want to give it another few pennies. The low of the Left Shoulder is 1.41, so this Right Shoulder should NOT go below that.
Good luck! I'd love to see this thing take off for you. You've done a very nice job on it. Applause.
Here's the MACD chart. Interesting how the price chart currently is a "fractal" (repeating pattern) of the Inverse H&S pattern here, which already broke out.
13/21 RSIs
Bocasva,
I like this chart so well, and like the fact that the 1.59 Buy Signal got printed on this morning's move to 1.62, that I decided to violate one of my rules (Don't Buy Illiquid Stocks), and put in an order to buy when ISV came back to fill the morning gap at BID 1.56...ASK 1.57.
My order is for ALL OR NONE at 1.57. You can see on the quote chart to the left that those jokesters IMMEDIATELY moved the stock to BID 1.57...ASK 1.59. That's why I hate to play illiquid stocks. They toy with you on the spread, and move the BID...ASK up on you (or down, if you're trying to sell).
At any rate, I'll leave my order in for 1.57, which should create a floor for you. :D >:D
ISV currently is BID 1.58...ASK 1.60
They're having fun, toying with me. ;D
Quote from: Melf Elf on December 01, 2006, 11:42:59 AM
Bocasva,
I like this chart so well, and like the fact that the 1.59 Buy Signal got printed on this morning's move to 1.62, that I decided to violate one of my rules (Don't Buy Illiquid Stocks), and put in an order to buy when ISV came back to fill the morning gap at BID 1.56...ASK 1.57.
My order is for ALL OR NONE at 1.57. You can see on the quote chart to the left that those jokesters IMMEDIATELY moved the stock to BID 1.57...ASK 1.59. That's why I hate to play illiquid stocks. They toy with you on the spread, and move the BID...ASK up on you (or down, if you're trying to sell).
At any rate, I'll leave my order in for 1.57, which should create a floor for you. :D >:D
ISV currently is BID 1.58...ASK 1.60
They're having fun, toying with me. ;D
Melf,
I know what you're talking about....I also hate playing hide and seek. Low volume stocks are harder/riskier to play, I usually buy limit AON at prior conservative known supports running the risk of not buying in at all but also limiting the risk and maximising the reward in case I get in.
Best of luck to you Melf.
Quote from: bocasva on December 01, 2006, 12:25:06 PM
Melf,
I know what you're talking about....I also hate playing hide and seek. Low volume stocks are harder/riskier to play, I usually buy limit AON at prior conservative known supports running the risk of not buying in at all but also limiting the risk and maximising the reward in case I get in.
Best of luck to you Melf.
Bocasva,
VERY wise of you.
I was watching trading in MDLK yesterday, a stock that trades only 8,000 a day! I've owned it for a long time, and noticed that a couple of 100,000 share blocks traded at 5.18 at 12:36PM, and at 5.20 at 12:38PM, and that the stock printed a six-year high, at 5.40.
Hmmm-mmm...it looked like something was up. That's HUGE volume for this stock.
Well, something else that was up, was that with the stock BID 5.05...ASK 5.20 (lousy spread) some poor guy got filled on 200 shares at 4.73, nowhere near the quote!!
That's awful. On 200 shares, he "only" got taken for $64, but I view that nonsense as no different than getting mugged on the street.
Sheesh! >:(
Anyway, I agree with you on passing on the trade, rather than getting yanked around like that. And, speaking of getting yanked around...
ISV currently is BID 1.59...ASK 1.60. They're not going to let me have it at 1.57. :( >:D
Good luck! I'll be cheering for you if I see 1.65-1.67 get knocked out to the upside. ;)
Chart is shaping up nicely.
Quote from: bocasva on December 03, 2006, 11:50:06 PM
Chart is shaping up nicely.
Bocasva,
It sure is!
Quote from: Melf Elf on December 01, 2006, 12:55:54 PM
Good luck! I'll be cheering for you if I see 1.65-1.67 get knocked out to the upside. ;)
ISV is right there, champing at the bit for a breakout. The high so far is
1.65. Volume is very low, only 15,000 shares in the first 25 minutes of trading, but if you get a print of 1.68, volume "should" come in.
ISV currently is BID 1.63...ASK 1.64
Good luck!
I second that motion !! ;D
Bouncing off the 50-day MA.....
Maintained support @ $1.50, hoping for no break....... ;)
52wk Range: 0.70 - 2.70
Volume: 285,600
Avg Vol (3m): 169,656
Technicals
Percentage Gainer
Last Price Quote is:
6.22%above 13-day MA
7.20%above 50-day MA
RS Rating: 10
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: Buy
Bocasva and Setravis,
I just realized that the chart of ISV is very similar to that of Holygrale's AUY, and potentially as bullish.
First, AUY:
It had a Bullish Inverse H&S breakout (pattern in green) to 11.38, which ended up being a false breakout for the time being.
AUY then formed the Double Bullish Inverse H&S patterns (in green), and here's the key: that 11.38 high became the pivot (middle) of a BIG "W" bottom, which recently broke out.
Next, I'll show you ISV, and you'll see what I mean.
The Ascending Triangle (pattern in blue) that had the false breakout in late August also could be seen as a Bullish Inverse H&S, depending upon how one wants to look at it, with those hits to the top of the Ascending triangle/neckline of an Inverse H&S at 1.80.
In either case it was a Bullish pattern, and a false breakout to 1.97 in late August, just like AUY had the false breakout to 11.38 in August.
If ISV can break out above 1.65-1.67 here, and rally to the 2.08 target that would be IN PLAY, picture what this chart will look like: 1.97 is the pivot (middle) of a BIG W-Bottom, just like 11.38 was the pivot in AUY, so that would be another bullish pattern breakout, above 1.97.
We'll see. If ISV had more volume, I would have paid the 1.59 ASK last Friday. They never filled me at my 1.57.
I'm still intrigued by the November 17 Bullish Inverse H&S breakout in the MACD. If it's acting as a "lead indicator," correctly telegraphing an impending Inverse H&S breakout in ISV itself, it sure lead by a wide margin. That breakout was nearly three weeks ago.
What's the delay here? Get going, dang it! :D
Quote from: Melf Elf on December 05, 2006, 03:34:11 AM
I'm still intrigued by the November 17 Bullish Inverse H&S breakout in the MACD. If it's acting as a "lead indicator," correctly telegraphing an impending Inverse H&S breakout in ISV itself, it sure lead by a wide margin. That breakout was nearly three weeks ago.
What's the delay here? Get going, dang it! :D
There's the technical breakout...
finally!! :D
Quote from: Melf Elf on December 01, 2006, 12:55:54 PM
Good luck! I'll be cheering for you if I see 1.65-1.67 get knocked out to the upside. ;)
I'm cheering for you guys! ;D
The print of
1.68 this morning is a breakout above the neckline, and a takeout of the prior high of
1.67. Now it needs VOLUME, and upside follow-thru.
Volume is only 28.000 shares.
ISV currently is BID
1.67...ASK
1.68.Good luck!
Quote from: Melf Elf on December 05, 2006, 10:01:58 AM
I'm cheering for you guys! ;D
Good luck!
Thanks Melf....ISV is still flirting at the breakout point waiting for new players to come in and ask her
up; we shall wait patiently as that could happen anytime now.
Quote from: bocasva on December 05, 2006, 10:52:57 AM
Thanks Melf....ISV is still flirting at the breakout point waiting for new players to come in and ask her up; we shall wait patiently as that could happen anytime now.
Bocasva,
ISV moved up a little, to 1.72, but no trades beween 11:07AM and 11:14AM (you have to look at this Time & Sales sheet to the left).
At 11:14AM, 9,000 shares were bought at the 1.72, and that seemed to bring in some buying interest. ISV gapped up from 1.72 to 1.75 on another 9,300 shares, at 11:17AM. Buyers are coming in, but again, you want to see more volume.
22 day average volume is 172,000 shares.
100 day average volume is 208,000 share, so you'd like to see at least 400,000 shares today, or better, for a breakout on two times daily volume.
So far, volume is 164,000 shares in the first 2½ hours of trading, so the run rate is on track for the 400,000 shares.
Looks good! 8)
Now that's an ugly shadow that I didn't want to see on ISV today.
1.65 should provide support for the next leg up. Volume was above average but not quite enough to move it violently to the upside.
Quote from: bocasva on December 05, 2006, 11:28:00 PM
Now that's an ugly shadow that I didn't want to see on ISV today.
1.65 should provide support for the next leg up. Volume was above average but not quite enough to move it violently to the upside.
Bocasva,
My sentiments exactly. What the heck was
thaa-at? :P
Volume was almost double average daily, which was good, but the close really should have been 1.68 or better, above the high of the 1.67-1.65 neckline, to consider it decisively broken out of the Inverse H&S pattern.
Players selling an obvious pattern breakout like that, all the way back to a 1.65 close, certainly wasn't what you wanted to see at all.
This 1.65 area "should be" support, as you say. The low of the Right Shoulder is 1.50, which
definitely shouldn't get taken down. Technically, if 1.49 gets printed, that's considered to be confirmation that it was a false breakout.
I'm still cheering for you, but I want to kick this stock's #$%#. :D >:D
Good luck!
This is what yesterday's candle should have looked like.....keep them coming.
Quote from: bocasva on December 07, 2006, 12:57:54 AM
This is what yesterday's candle should have looked like.....keep them coming.
Bocasva,
My sentiments exactly. :D
For a minute there, when it was printing the low 1.60s again, they had me worried that it was another false pattern breakout, like late August.
Volume could have been a little better, but it still was above average. Pretty candle, though, closing at the high of the day, well above the neckline, and well above the Kumo (Cloud).
Because the 1.67 - 1.65 neckline has a slight downward slope, the technical breakout was above 1.64, so that puts a target 2.06 IN PLAY (math is on the chart), as long as ISV trades above that neckline breakout.
If 2.06 gets MADE, that's a takeout of 1.97, the pivot of the BIG W-Bottom, which would put a target of
2.70 IN PLAY.
Math:
1.97 - Pivot High
1.24 - (The more conservative of the 1.24 and 1.20 Double Bottom)
1.97 - 1.24 = 0.73 Points + 1.97 = Target:
2.70Interestingly, the May 26, 2006 high was
2.70 exactly, so ISV would have the pattern strength and measured move off a breakout for a re-test.
Good luck!
Quote from: Melf Elf on December 07, 2006, 01:55:50 AM
....If 2.06 gets MADE, that's a takeout of 1.97, the pivot of the BIG W-Bottom, which would put a target of 2.70 IN PLAY...
2.70?? Wow, the little devil inside me started getting greedy when I read your post. >:D
If volume starts incrementing over the next sessions 2.70 is very realistic. My original target had been 1.96 but I just have to let the chart do the talking.
Quote from: bocasva on December 07, 2006, 12:29:14 PM
2.70?? Wow, the little devil inside me started getting greedy when I read your post. >:D
Bocasva,
Sorry, I didn't mean to tempt your greed devil. >:D Hee hee hee. :D
My greed devil is annoyed that they didn't fill me at back 1.57. >:D >:(
I'd have a paper gain of nearly 15% here. Curses! >:D
Quote
If volume starts incrementing over the next sessions 2.70 is very realistic.
Volume was just "okay" on the breakout. Yesterday was an improvement to a little better than 2 times ADV, so that's good. Blocks of 5,000 and 10,000 were able to go off with the added liquidity, so it attracts more buyers.
That's the problem that I had getting filled at 1.57 the other day. No volume to speak of, so they moved the BID...ASK away from me.
Quote
My original target had been 1.96 but I just have to let the chart do the talking.
You will have a very nice paper gain at that price, so you might want to stick with your plan and take some there, to protect your profits, just in case it Double Tops near 1.97, and the 2.06 target doesn't get MADE, let alone the 2.70. You never know...
I do think that if there's even a hint of good news from the company, the technical traders will have to like this chart, and will step in and buy a breakout. They did a little bit of that the past few days, on the breakout of the Bullish Inverse H&S.
Pretty chart. A breakout above 1.97 on volume would be
very pretty.
Continued good luck!
Bocasva,
Some nice buying interest coming in.
13,500 shares at 1.85...15,300 shares at 1.87...
The run rate on volume is close to 2 times average daily.
Bocasva,
Steadily creeping back toward the 1.97 high...
You've got a very nice trade going here.
How's your Greed Devil doing? >:D :D
Quote from: Melf Elf on December 08, 2006, 04:10:09 PM
Bocasva,
Steadily creeping back toward the 1.97 high...
You've got a very nice trade going here.
How's your Greed Devil doing? >:D :D
Thanks Melf Elf.
Let's hope ISV keeps behaving nice and hits our targets.
I went to church today to try to keep that little devil in control, hehehehe.
Today's shakeout should help consolidate ISV to continue its upward movement.
Quote from: bocasva on December 13, 2006, 01:04:28 AM
Today's shakeout should help consolidate ISV to continue its upward movement.
LOL, talk about shakeouts, I was shakenout at 1.68(luckily).
WOW, what a day; it went from 1.87 to 1.32
Quote from: bocasva link=topic=646.msg80925#msg80925
LOL, talk about shakeouts, I was shakenout at 1.68(luckily).
WOW, what a day; it went from 1.87 to 1.32
Bocasva,
Whoa! You still have a nice gain at 1.68, though. Good going. Applause.
Setravis,
excellent call on ISV where do you see it going now?
up to 1.9$ AH >:D >:D
why?
InSite Vision Announces Patent Agreement With Pfizer
Thursday February 15, 4:00 pm ET
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV - News) -- an ophthalmic therapeutics, diagnostics and drug delivery company, today announced that it has entered into a worldwide, exclusive royalty bearing licensing agreement with Pfizer Inc. (NYSE:PFE - News) under Pfizer's Patent family titled "Method of Treating Eye Infections with Azithromycin". Pfizer's granting of this license will enhance the position and marketability of InSite's AzaSite franchise.
S. Kumar Chandrasekaran, Ph.D., InSite Vision's chief executive officer stated, "The execution of the Pfizer license represents a significant milestone in the development of InSite Vision's AzaSite franchise. Combined with our existing azithromycin and DuraSite drug-delivery patents, this license further broadens InSite Vision's global patent portfolio."
Under the terms of the agreement, Pfizer will grant InSite a worldwide, exclusive license, including the right to sublicense, to U.S. and all foreign counterparts patents on the parent case titled "Method of Treating Eye Infections with Azithromycin" and patent applications together with any reissues, extensions, or supplementary protection certificates of any of the foregoing for use in connection with InSite's AzaSite franchise products.
Quote from: la-onda on February 16, 2007, 02:30:20 AM
up to 1.9$ AH >:D >:D
why?
InSite Vision Announces Patent Agreement With Pfizer
Thursday February 15, 4:00 pm ET
Oliver,
1.90305 is the top of an 8-Month Symmetrical Triangle (pattern in black) for today, February 16, so a print of 1.91 is a technical breakout, which would put 2.67 IN PLAY (math for the target is at the upper right on the chart).
Within the Symmetrical Triangle, ISV formed TWO Inverse H&S patterns (one in blue, the other in purple). Both broke out; both were failures. They now are nested within the large Symmetrical Triangle, so ISV is packing some punch, technically, if it can break out on the print of 1.91.
The prior highs of 1.97 and 1.93 obviously need to get taken out to the upside, but if volume comes in, this could be a "Gap and Go" opening, rather than a "Gap To Crap" since it's a technical breakout of a strong 8-month base.
Good luck!
Shorts should be gone.......
Could be a nice little base put in here @ the $1.40 area.
InSite's topical anti-infective product currently under NDA review by the FDA for the treatment of bacterial conjunctivitis; commonly referred to as "pink eye". The global market opportunity for topical, ocular anti-infective products currently exceeds one billion dollars.
52wk Range: 1.20 - 2.70
Volume: 665,400
Avg Vol (3m): 282,246
Technicals
Close Above the 13-day MA
Percentage Gainer
RS Rating: 24
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: 05/10/2007
Last Analyst Rating: Buy
ISV has several caveats of concern but the volume action is triggering a buy signal.
Maintaining support,
Closed above the 13/50/200-day MA's
On the 6 month chart looks to have placed a Double Bottom.......
On the 1 year chart the Symmetrical Triangle "coil look"...looking for bounce !
Volume: 2,214,700
Avg Vol (3m): 348,160
Market Cap: 159.49M
Technicals
Most Actives
Percentage Gainer
Last Price Quote is:
12.90%above 13-day MA
11.24%above 50-day MA
RS Rating: 81
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: 08/13/2007
Last Analyst Rating: Buy
Below are the 6 month and 1 year charts.......
Hi,
Buying large percentage of portfolio into ISV right now.
The call should bode very well.
Looking for 30 cent move near term, imo.
;D
• Q2 2007 InSite Vision Incorporated Earnings Release - Time Not Supplied
CCBN (Wed 7:07am
52wk Range: 1.24 - 1.97
Volume: 395,400
Avg Vol (3m): 337,618
Technicals
Close Above the 13-day MA ....... ;)
Last Price Quote is:
2.43%above 13-day MA
-2.68%below 50-day MA
RS Rating: 20
Fundamentals
Earnings Expected on Aug 8
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: 11/13/2007
Last Analyst Rating: Buy
Below are the 6 month , 2 year and 3 year charts.......
Call is 5:00 EST
Press Release Source: InSite Vision Incorporated
InSite Vision Reports Second Quarter 2007 Financial Results
Wednesday August 8, 4:05 pm ET
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV - News), an ophthalmic therapeutics, diagnostics and drug delivery company, today reported financial results for the three months ended June 30, 2007.
Net income for the second quarter ended June 30, 2007 is $2.2 million, or $0.02 per share, compared to a net loss of $5.1 million or $ 0.06 per share for the second quarter 2006. The difference was attributed mainly to the recognition of deferred revenue related to the licensing of AzaSite(TM) (1% azithromycin ophthalmic solution) to Inspire Pharmaceuticals and the milestone payment, received following the signing of the agreement and approval of AzaSite(TM) by the FDA on April 27, 2007.
Research and development (R&D) expenses were $2.1 million for the second quarter 2007, compared to $2.8 million in the same quarter in 2006.
Selling, general and administrative (SG&A) expenses increased to $2.1 million in the second quarter 2007, compared to $1.7 million in the same quarter in 2006.
InSite Vision had cash and cash equivalents of $18.9 million at June 30, 2007, compared to $986,000 at December 31, 2006.
For the six months ended June 30, 2007, the Company reported a net loss of $416,000 or, $0.00 per share compared to a net loss of $10.5 million or $0.12 per share for the six months ended June 30, 2006.
Research and development expenses decreased to $3.9 million for the first six months of 2007, compared to $6.0 million in the first six months of 2006. This was due largely to a decrease in external service expenses, which had been primarily related to the AzaSite clinical trials, preparation of the related NDA and the filing fee in 2006.
Selling, general and administrative expenses increased to $3.7 million for the first six months of 2007 compared to $3.4 million in the first six months of 2006.
"With the approval and imminent launch of AzaSite(TM), InSite Vision is at a pivotal point in our business. By leveraging our DuraSite technology and the revenue from AzaSite commercialization, we believe that we have technological and financial capabilities to expand and advance our product pipeline and lead us to profitability and growth," said S. Kumar Chandrasekaran, PhD, chief executive officer, InSite Vision
It seems that ISV may be positioned for sale.
Watch trading and volume the next day or so.
;D
Report the summarizes much of what they said tonight...
http://www.mikehav.com/isv8aug07note.pdf
ALAMEDA, Calif., Sep 11, 2007 (BUSINESS WIRE) -- InSite Vision Incorporated (ISV, Trade), an ophthalmic therapeutics company, today announced that S. Kumar Chandrasekaran, Ph.D., President and Chief Executive Officer, will present an overview of the company at the ThinkEquity Partners' Fifth Annual Growth Conference, Wednesday, September 19, 2007 at 8:30 a.m. Pacific Time in San Francisco, Calif.
The presentation will be webcast and may be accessed live on the investor relations section of the company's website at www.insitevision.com. The presentation will be available on this link for a limited time following the conference.
InSite Vision develops novel ophthalmic products including AzaSite(TM) (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis recently launched by Inspire Pharmaceuticals. Based on its proprietary DuraSite(R) topical sustained-release technology, InSite is expanding its portfolio of ophthalmic products to include AzaSite Plus(TM) and AzaSite Xtra(TM) with the potential to provide significant advantages currently not available with conventional treatment options. Additionally AzaSite Otic(TM) is under development for ear infections.
SOURCE: InSite Vision Incorporated
InSite Vision Incorporated
Joyce Strand, 510-747-1220
Copyright Business Wire 2007 ********************************************************************** As of Friday, 09-07-2007 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated an UPTREND on 08-07-2006 for ISV @ $1.73. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2007 Comtex News Network, Inc. All rights reserved.
Technicals
Close Above the 13-day MA
Percentage Gainer
Last Price Quote is:
2.79%above 13-day MA
-8.35%below 50-day MA
RS Rating: 9
Fundamentals
Key Data:
Market Cap (M): $30.56
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: 11/13/2007
Last Analyst Rating: Buy